Novavax is seeking approval for use of its COVID-19 jab in Singapore. If interim permission is granted, it will be the first protein-based coronavirus shot available locally under the Special Access Route. The jab has shown promising results in overseas trials. Prof Ooi Eng Eong from the emerging infectious diseases programme at Duke-NUS Medical School shared his thoughts on protein-based vaccines and how likely they will hold up against coronavirus variants.
Subscribe to our channel here: https://cna.asia/youtubesub
Subscribe to our news service on Telegram: https://cna.asia/telegram
Follow us:
CNA: https://cna.asia
CNA Lifestyle: http://www.cnalifestyle.com
Facebook: https://www.facebook.com/channelnewsasia
Instagram: https://www.instagram.com/channelnewsasia
Twitter: https://www.twitter.com/channelnewsasia
0 Comments